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Smita Bhatia,1 Stella M. Davies,2 K. Scott Baker,3 Michael A. Pulsipher,4 John A. Hansen3Hematopoietic cell transplantation (HCT) is now a curative option for certain categories of patients with
hematologic malignancies and other life-threatening illnesses. Technical and supportive care has resulted
in survival rates that exceed 70% for those who survive the first 2 years after HCT. However, long-term sur-
vivors carry a high burden of morbidity, including endocrinopathies, musculoskeletal disorders, cardiopulmo-
nary compromise, and subsequent malignancies. Understanding the etiologic pathways that lead to specific
post-HCT morbidities is critical to developing targeted prevention and intervention strategies.
Understanding the molecular underpinnings associated with graft-versus-host disease (GVHD), organ
toxicity, relapse, opportunistic infection, and other long-term complications now recognized as health
care concerns will have significant impact on translational research aimed at developing novel targeted
therapies for controlling chronic GVHD, facilitating tolerance and immune reconstitution, reducing risk of
relapse and secondary malignancies, minimizing chronic metabolic disorders, and improving quality of life.
However, several methodological challenges exist in achieving these goals; these issues are discussed in detail
in this paper.
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Progress in hematopoietic cell transplantation
(HCT) over the last 30 to 40 years has resulted from
improvements in several areas, notably better support-
ive care and less toxic conditioning regimens. It is for
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6/j.bbmt.2011.07.005a curative option for patients with hematologic
malignancies and other life-threatening illnesses. Ad-
vances in how HCT is performed and how patients
are supported in the immediate post-HCT period,
have resulted in survival rates that exceed 70%
for those who survive the first 2 years after HCT
[1-3]. However, full restoration of health does
not necessarily accompany cure or control of the
underlying disease. Endocrinopathies, musculoskeletal
disorders, cardiopulmonary compromise, and sub-
sequent malignancies are well described in HCT
survivors [4-13]. In fact, the cumulative incidence of
a chronic health condition among HCT survivors is
reportedly 59% (95% confidence interval [CI]: 56%-
62%) at 10 years after HCT; for severe/life-
threatening conditions or death because of chronic
health conditions, the 10-year cumulative incidence ap-
proached 35% (95%CI: 32%-39%) [14]. Furthermore,
HCT survivors with chronic graft-versus-host disease
(cGVHD) are 5 times as likely to develop severe/life
threatening conditions. Understanding the burden of
morbidity carried long term by the HCT survivors is
important to the healthcare providers and policymakers
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care of these patients; it is important to the researchers in
identifying etiologic pathways that lead to themorbidity;
and finally, it is important to the HCT survivors in
helping them make informed decisions regarding the
quality-of-life concerns in the long term after HCT.
Understanding the etiology and pathogenesis
of long-term complications in survivors of HCT per-
formed in childhood is important for a variety of
reasons. It is well established that exposure to geno-
toxic agents during the earlier years of life has a signif-
icant impact on the structure and function of the
developing organs. Examples of this abound in the
children treated with conventional therapy, and
include the higher risk of anthracycline-related
cardiotoxicity, of radiation-related cognitive impair-
ment, and of radiation-related second malignancies
when the exposure occurs at a younger age. However,
large-scale studies attempting a comprehensive under-
standing of the etiology and pathogenesis of long-term
complications after HCT performed in childhood are
lacking. There are several methodologic challenges
that have precluded the conduct of such studies, the
first and foremost is the fact that large cohorts of
patients need to be assembled to address these issues.
The following sections describe the methodologic
challenges in the conduct of such studies, drawing
upon studies conducted in adult populations as exam-
ples of how such studies can be accomplished.MAGNITUDEOFRISKOFCHRONICMEDICAL
CONDITIONS AFTER HCT
In order to describe the magnitude of risk of
chronic medical conditions after HCT with precision,
it is critical to assemble large cohorts of children who
have undergone HCT, with near complete follow-up.
The emphasis on large cohorts is because of the fact
that HCT survivors represent a heterogeneous popu-
lation; therefore, understanding the magnitude of
risk in homogeneous subpopulations necessitates the
assembly of a large cohort. Most of the large studies
use registry data. Registry data is limited by the passive
reporting of the outcome of interest, inability to vali-
date the outcome, and incomplete follow-up of the pa-
tients, thus resulting in imprecise measurements of
risk. These limitations can be overcome by the estab-
lishment of a consortium of institutions dedicated to
the study of late effects and with available resources
to ensure complete and accurate follow-up of the pa-
tients under consideration.COMPREHENSIVE EXPOSURE ASSESSMENT
Studies focusing on children treated with conven-
tional therapy have established the role of therapeuticexposures as the primary etiologic factor in the devel-
opment of long-term complications quite conclu-
sively. This is exemplified by the dose-dependent
association between anthracyclines and congestive
heart failure, radiation and secondary breast cancer
or brain tumors, or thyroid cancer. It would therefore
follow that adverse events after HCT would be due
in part to the pre-HCT therapeutic exposures,
HCT-related conditioning, and post-HCT exposures
(chemotherapy, radiation, or immunosuppressive
therapy). However, for the most part, previous reports
describing post-HCT complications have failed to
take into account the pre-HCT therapeutic exposures,
thus increasing the risk of creating imperfect associa-
tions between the HCT process and the outcome of
interest, when the true association was in part related
to the pre-HCT exposures. Obtaining pre-HCT expo-
sures can be challenging for a large cohort of HCT
survivors, and 1 way of overcoming this challenge is to
conduct a nested case–control study within the cohort—
with abstraction of detailed pre-HCT therapeutic
exposure limited to the cases and matched controls.VALIDATION OF OUTCOMES OF INTEREST
When assessing outcomes of interest, it is critical
that methodologies be established initially regarding
how these outcomes will be identified and whether
there is a process in place for validating the outcome.
Under ideal circumstances, there would be stringent
criteria established initially to validate the outcome
of interest. Typically, this would include a pathology
report (with cytogenetics where appropriate) for sec-
ond malignancies and echocardiographic evidence of
cardiomyopathy (with established cutoffs in ejection
fraction and fractional shortening for defining cardiac
dysfunction). If the outcome of interest is elicited by
self-report, it should be stated clearly in the report,
along with the attendant limitations.DEVELOP CLEAR RELATION BETWEEN
EXPOSURE AND OUTCOME
Utilization of the methodology described above
will allow the establishment of a clear relation between
exposure and outcome, and will also allow a clear
delineation of the independent contribution of
pre-HCT versus HCT-related versus post-HCT
exposures. Having such a relationship then allows the
exploration of the interindividual variability in risk,
given constant exposure. Such interindividual varia-
bility is clearly observed in patients treated with
anthracyclines, where doses exceeding 1000 mg/m2
are tolerated by some, whereas low doses (\150mg/m2)
result in congestive heart failure in the others. Initially
identifying those at highest risk becomes critical in
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This maximizes the chance of cure, while minimizing
the long-term toxicity—the basis for ‘‘personalized
medicine.’’ In addition, understanding the pathoge-
netic mechanism underlying the development of an
outcome of interest, given a therapeutic exposure,
would allow for the development of novel therapeutic
interventions, allowing for early detection and poten-
tial reversal of the process.
Advances in genetics research has also been a sig-
nificant contributing factor in defining the human ma-
jor histocompatibility system (HLA) and high-impact
translational research that has guided donor selection
and refined, through the development of DNA-based
tools for high-resolution genotyping, robust criteria
for the optimal selection of HLA-matched unrelated
donors [15,16]. However, despite precise matching
for HLA, graft-versus-host disease (GVHD), opportu-
nistic infection, and other complications remain signif-
icant obstacles to safety and overall success. Genetic
polymorphism is responsible not only for HLA mis-
matching between donor and recipient, but also for
the mismatching of a potentially large number of
minor histocompatibility antigens encoded by genes
located across the genome [17,18]. Genetic variants
encoding minor histocompatibility antigens include
single nucleotide polymorphisms (SNPs) responsible
for amino acid substitutions in cellular proteins that
can function as minor histocompatibility antigens
[18], or deletions in genes that abrogate protein pro-
duction and thereby alter donor and recipient disparity
for minor histocompatibility antigens as illustrated in
a recent article by McCarroll et al. [19]. In addition
to genetic polymorphism causing recipient and donor
disparity, certain polymorphisms can also affect gene
function. Many SNPs have been identified, both inter-
genic and in nearby promoter regions, that modify
gene function by changing expression levels, modify
functional amino acid substitutions, or cause alterna-
tive splicing of gene transcripts, all of which may alter
gene function [20].
To develop a deeper understanding of the mole-
cular underpinnings of therapy-related long-term
complications, it becomes important to collect appro-
priate biospecimens from the patients who do and do
not develop the outcome. Ideally, this should be inTable 1. Comparison of Candidate Gene and Genome-Wide Study
Candidate Gene Studies
Rational selection of genes for study increases biological plausibility
of findings; however, novel genes will not be identified.
Limited number of genes reduces the possibility of false discovery.
Expense reduced if candidate genes selected prove to be relevant to outcome.
Moderate sample size may be sufficientthe form of blood, which would be collected to allow
subsequent extraction of DNA and RNA, as well as es-
tablished lymphoblastoid cell lines. In patients under-
going allogeneic HCT, the blood should be collected
before HCT, in order to reflect the DNA of the
host. Study of GVHD ideally would require the collec-
tion of paired DNA from the host and donor. There
are 2 approaches to the study of genetic variation in
disease: (1) candidate gene studies based on the selec-
tion of a limited number of tag SNPs for analyzing spe-
cific genes and pathways, and (2) genome-wide
association studies (GWAS) usingDNA arrays capable
of detecting a million or more SNPs.
Both approaches have attendant strengths and
limitations. Candidate gene studies are both com-
plementary and additive to genome-wide studies.
Table 1 compares the characteristics of both strategies.
A GWAS approach offers the ability to study complex
pathways, allowing for an assessment of the action/
interaction of many genes; it also allows for new genes
to be identified. GWAS has gained significant favor,
partly because of the fact that several studies that
have utilized a candidate gene approach have failed
replication. However, a GWAS approach requires
a large sample size in order to account for false discov-
ery. In addition, there is a need for a replication cohort,
so that the genes identified in the discovery set can be
validated in the test set.
The GWAS approach does not have an a priori
hypothesis, and is considered to be hypothesis-
generating and more suited for complex disorders
where a clear etiologic lead is not established. How-
ever, this is not true for many post-HCT outcomes,
where for the most part there is a clearly established
etiologic association between the exposure and out-
come (eg, radiation and subsequent malignancies). In
such cases, an argument could be made for a compre-
hensively selected (and biologically plausible) list of
genes identified along the path of the action of radia-
tion on the target organ. As mentioned earlier,
GWAS is limited by the need for a large sample size
because of issues related to multiple testing—this is
less of an issue with a candidate gene approach. Finally,
gene–gene interactions may require prohibitively large
samples in aGWAS setting, but are logistically feasible
when conducting a candidate gene study.Approaches
Genome-Wide Studies
Analysis of whole genome allows identification of genes not previously
thought to be important for the outcome in question.
Large number of analyses means a high risk of false discovery.
Increased expense associated with following up the large number
of positive findings.
Very large sample sizes are needed because of the large number
of comparisons being made.
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LATE EFFECTS AFTER HCT
Genetic polymorphisms can influence the outcome
of transplantation by modifying the function of the
gene, and many studies have evaluated genetic variants
that modify expression of key cytokines, a plausible
mechanism for modification of outcome. The first
studies commonly explored 1 variant, and many in-
cluded relatively small numbers of heterogeneous
cases. Many (perhaps most) of the positive findings of
these studies have not been replicated in later studies.
Difficulties in replicationmay indicate that the original
findings were simply statistical chance, that the finding
is true but specific to particular populations or trans-
plantation strategies, or that there may be gene–gene
interactions that modify observations. In addition to
modifying gene function, polymorphisms may serve
as minor antigens. There are several examples of stud-
ies that have utilized the candidate gene approach in or-
der to understand the molecular underpinnings of
disease. These examples are illustrated here.
Analysis of GVHD
Several candidate gene studies have generated data
showing that genetic variation can affect the risk of
GVHD. More than 26 publications have appeared be-
tween 1998 and 2009 reporting associations of donor
or recipient genotypes with the risk of acute GVHD
(aGVHD) for 30 candidate SNPs in 16 genes includ-
ing: CD31, CTLA4, FAS, HSPA1L, IL1a, IL1b,
IL2, IL23R, IL6, IL10 [21], IL10RB [22],
MADCAM1, MTHFR, NOD2, TGFb1, TNF,
TNFRII, and VEGFa. Previous candidate gene stud-
ies, however, have been generally limited to relatively
small study populations of a few hundred patients
and donors, and the results have not been consistent.
Nevertheless, the resulting publications have indelibly
influenced the research agenda and demonstrated the
need for more comprehensive and robust approaches
to identifying specific genetic variations associated
with transplantation outcome. Clinical risk assessment
models have advanced significantly in the last few
years, especially in the identification and properTable 2. Studies Reporting the Association of CD31 Polymorphism
Reference Stem Cell Source #
Behar et al., NEJM, 1996 Sibling marrow, Stanford, U.S. 46
Nichols et al., Blood 1996 Sibling marrow, U.S. Multicenter 301
Maruya et al., Blood, 1998 Sibling marrow, Japan 118
Grumet et al., BBMT, 2001 Sibling marrow, Stanford, U.S. 120
Rocha et al., Blood, 2002 Sibling marrow, France 107
Kogler et al., Transplantation, 2002 Unrelated donor cord blood 115
Balduini et al., Br J Haematol, 2001 Sibling marrow, Italy 150
Goodman et al., Bone Marrow
Transplantation, 2005
Sibling marrow, U.K. 85weighing of relevant clinical variables, but the ‘‘genetic
effect’’ remains largely undefined and unmeasured.Analysis of Opportunistic Infection and Air Flow
Obstruction (AFO)
In addition to aGVHD, candidate gene studies have
been used to productively explore genetic risk factors in
other clinically important complications of HCT. The
Seattle group has used the candidate gene approach in
an analysis of Gram-negative bacteremia and identified
variation in the LBP gene to be associated with risk of
Gram-negative bacteria and death [23]; fungal disease
implicating variation in the TLR4 gene with risk of in-
vasive aspergillosis [24]; and AFO disease of the lungs
[25]. AFO, also known as bronchiolitis obliterans syn-
drome, is a serious and often fatal complication of
cGVHD, which compromises pulmonary function
and quality of life [26-28]. Fifteen candidate genes
involved in the innate immunity pathway were
examined in a discovery cohort of 363 patient–donor
pairs. Significant associations were found in multivari-
ate models for 2 SNPs in the BPI gene of the patient
(SNP 33065, P 5 .038; and SNP 36045, P 5 .025);
and this association was confirmed in an independent
validation cohort, with 9 BPI SNP-defined risk haplo-
types identified (P values .013-.043) [25].
Candidate gene studies exploring genetic associa-
tions with complications and late effects of transplanta-
tion have been reported for more than 15 years, and yet
the findings have yet to be included in clinical practice.
Technology to perform genotyping on a large scale has
advanced rapidly, and, in common with candidate gene
studies, has perhaps surpassed our ability to interpret
results and incorporate them into clinical practice.
The challenge of understanding the impact of poly-
morphisms on outcomes is illustrated by the complex-
ities of the genetic polymorphisms in gene CD31.
Behar and colleagues [29] reported a case–control
study in 1996, showing that disparity between recipi-
ent and donor for a polymorphism (SNP 125) in
CD31 increased the risk of GVHD (Table 2). A larger
study published in the same year showed no effect of
the variant [30]. Later, studies performed in Japans with GVHD Risk
Conclusion
CD31 SNP 125 is an important minor antigen.
CD31 SNP 125 is NOTan important minor antigen.
CD31 MIGHT be an important minor antigen due to SNPs 563/670.
CD31 IS a minor antigen, and polymorphism at SNPs 563/670 is
more important than SNP 125.
CD31 polymorphism at SNPs 563/670 is a minor antigen.
CD31 polymorphism at SNP 125 has no impact on clinical outcomes.
CD31 polymorphism at SNP 563 is a minor antigen.
No effect of CD31 SNPs 125 or 563/670 as minor antigens,
but CD 125 genotype is correlated with GVHD risk,
suggesting a functional effect.
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equilibrium with other SNPs (SNP 563 and 670) and
that these linked variants were driving the association
[31,32], although a study of unrelated donor cord
blood transplants showed no effect [33]. A more recent
British study found that disparity for CD31 polymor-
phisms did not associate with outcomes, but that the
genotype for SNP 125 was associated with the risk of
GVHD [34]. These authors suggest that the variant
CD31 genotype had an effect on T cell function.
These studies, which include 15 years of work, offer
no clarity regarding the clinical importance or mecha-
nism of action of variants in a single gene, illustrating
the complexity of translation of laboratory findings
into clinical practice.
The utility of genetic variants that predict the risk
of complications may allow selection of an optimal do-
nor. However, it should be recognized that in some
patients there are limited donor choices, and it is
highly unlikely that studies will identify variants that
would be more important than the dominant effect
of HLA-matching, limiting the clinical usefulness of
alternative strategies for donor selection.
Genetic association studies do offer the opportu-
nity to explore the biology of transplant complications,
and may allow identification of novel drug targets. For
example, recent work by Ostrovsky et al. [35] has
shown an association between heparanase genotype
and GVHD, identifying this molecule as a potential
target for GVHD therapy.
Single-gene disorders, such as Fanconi anemia and
dyskeratosis congenita, also have an important impact
on the outcome of transplantation, with an attributable
risk much greater than that likely to be associated with
a population polymorphism. Recognition of these dis-
orders before transplantation plays a critical role in
avoidance of specific toxic exposures (eg, radiation,
busulfan) and modification of dosing. When the char-
acteristic physical abnormalities are present, diagnoses
are usually made but can be overlooked in patients pre-
senting late, particularly in adult centers unfamiliar
with these disorders. The availability of telomere test-
ing has improved the recognition of dyskeratosis con-
genita, as physical manifestations may appear after
marrow failure.
In summary, candidate gene studies require prior
knowledge (or at least a hypothesis) regarding which
pathways are important. The key strength of a
genome-wide approach is the ability to make new
discoveries. It should be recognized, however, that
positive findings in a genome-wide study become can-
didates for replication in a candidate gene study.GWAS
Over the last decade, there has been extraordinary
progress in the development of methods and tools forthe characterization of the human genome. The recent
completion of the human genome map [36,37] and the
development of dense SNP marker maps of the
genome [38,39], as well as development of massively
parallel genotyping technologies [40-42], have made
it possible to screen genes in an unbiased manner
for polymorphisms that correlate with phenotype,
disease status, and relevant quantitative traits. Consi-
deration of the entire genome in an unbiased fashion
permits the discovery of genetic determinants, genes,
and pathways that would have never been considered
otherwise.
Estimation of Statistical Power for Genetic
Association Studies
The statistical power question has been mostly ig-
nored in previous candidate gene studies, and the use
of inadequately powered study populations has un-
doubtedly been a critical issue leading to many false
positive results. Statistical power is an even greater is-
sue for GWAS when the number of genetic factors
tested for association approaches 1 million or more
SNPs. An example of the study sample size needed to
adequately power a GWAS is illustrated by the esti-
mated statistical power to be gained by increasing
the sample size from 1500 to themore than 5000 trans-
plant pairs (Figure 1). Given a phenotype with a 30:70
distribution, such as cGVHD or grades 2 to 4
aGVHD, a sample size of 1500 provides 60% to
80% power to observe a 2.0 relative risk for SNPs
with a minor allele frequency (MAF) of 0.10 to 0.40,
whereas a sample size of 5000 is necessary to detect
a 1.5 relative risk, after the necessary correction for
multiple comparisons. For a phenotype with a 15:85
distribution, such as grade 3 to 4 aGVHD, a sample
size of 1500 provides 60% to 80% power to observe
a 2.4 to 2.5 relative risk for SNPs with an MAF of
0.10 to 0.30, whereas a sample size of 5000 provides
similar power to observe a 1.6 to 1.7 relative risk. Rel-
ative risks in the range of 1.5 to 1.7 are consistent with
values previously reported by Lee et al. [15] for the ef-
fect size of HLA mismatching and mortality estimated
in amulticenter NMDP study of 3857 unrelated donor
HCT cases.
GWAS in HCT
Two preliminary publications have appeared for
GWAS of HCT, 1 by the Japanese group lead by
Ogawa [43] and 1 summarizing preliminaryGWAS re-
sults for the first 1500 patient–donor pairs from the Se-
attle HCT cohort [44]. Overall, the Seattle results
demonstrate that genes and pathways associated with
clinically significant HCT outcomes can be identified;
however, the size of the initial GWAS cohort was not
sufficiently large and lacked statistical power for
measuring effect sizes with magnitudes of risk\2.0.
Figure 1. Improvement in statistical power by increasing the sample size from 1500 samples (black lines) to 5000 samples (red lines). Horizontal gray
lines indicate relative risks of 1.5 and 2.0. Panels show results for SNPs with minor allele frequencies (MAF) ranging between 0.10 and 0.40.
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single-center GWAS-HCT project to include a total
of 5000 HCT donor–recipient pairs, anticipating
that data generated will provide important information
for assessing risk, patient counseling, and treatment
planning, as well as provide insight into the basic me-
chansims responsible for transplant complications and
rationale for new targeted therapies.PLANNING FUTURE GENETIC STUDIES
Key issues that need to be addressed include (1)
study design beginning with a precise definition of
the endpoints or phenotypes, (2) identification of an
appropriate and adequately sized study population
together with a reliable plan for collecting and main-
taining high-quality DNA, and (3) selection of an
appropriate approach or platform for genotyping.
Study Design
If the intent is to analyze a single endpoint (eg,
cGVHD), a case–control study design would be the
most efficient; however, a cohort design would be
more appropriate for the study of complex or multiple
phenotypes. Furthermore, consideration should be
given to issues related to survival bias when designing
prevalent case–control studies, especially where the
endpoint is associated with a high lethality rate. Study
design must include rigorous power estimations to
determine the number of subjects necessary to meet
statistical objectives.
Study Population
Registration of transplant patients for a cohort
would ideally begin before transplantation to assure
complete ascertainment of the population at risk and
collection of DNA samples from both patients and
donors. Prospective enrollment has the advantage of
minimizing sampling bias, obtaining appropriate con-sent for genetic studies, and facilitating when feasible
the establishment of a biorepository for long-term
sustainable maintenance of cells and/or DNA.
Genetic Analysis
A candidate gene approach should be guided by
a specific hypothesis and relevant preliminary data,
whereas a genome-wide approach is necessary for
comprehensive discovery analysis. If limited to a few
genetic variants, the candidate gene approach has the
advantage of requiring a relatively smaller study popu-
lation and being less costly compared with a genome-
wide discovery approach (a few dollars per SNP for
genotyping 1000 samples, multiplied by the number
of SNPs), whereas a GWAS requires a much larger
number of study samples and is more costly ($200-
$400/sample for1million SNPs). Customized arrays
or ‘‘ImmunoChip’’ are also available that identify a few
thousand SNPs, many of which have been previously
shown to represent markers for association with
immune-mediated diseases. The NIH maintains 2 re-
lated GWAS databases, 1 known as the case–control
GWAS database (https://gwas.lifesciencedb.jp/cgi-bin/
gwasdb/gwas_top.cgi) that catalogs a growing number
of SNPs associated with different diseases including
cardiovascular and metabolic disorders, and a second
known as dbGaP (http://www.ncbi.nlm.nih.gov/gap)
that maintains detailed genotype and phenotype data
for NIH-supported GWAS projects.SUMMARY
The discovery of markers and functional variants
associated with HCT outcomes will have significant
implications for future translational research aimed
at improving risk assessment and directingmechanistic
research. Identification of new and informative genetic
markers for HCT complications will have utility in the
clinical setting for further strengthening objective
1434 Biol Blood Marrow Transplant 17:1428-1435, 2011S. Bhatia et al.pretransplantation risk assessment and patient coun-
seling, and serving as valuable tools for clinical man-
agement and treatment planning. The discovery of
previously unrecognized functional variants defining
genes and pathways associated with GVHD, organ
toxicity, relapse, opportunistic infection, and other
long-term complications now recognized as emerging
health care concerns will have significant impact on
translational research aimed at developing novel tar-
geted therapies for controlling cGVHD, facilitating
tolerance and immune reconstitution, reducing risk
of relapse and secondary malignancies, minimizing
chronic metabolic disorders, and improving quality
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